1st POSTGRADUATE

CLL Conference


Bologna, November 13-14, 2017

Monday, November 13, 2017

Session I - Genomic Landscapes

Chairmen: N. Chiorazzi, G. Gaidano

C.M. Croce

CLL pathogenesis: a cooperation between microenviroments and genetics

N. Chiorazzi

Genetic portrait of CLL

D. Rossi

Predictive biomarkers

Session II - Chemoimmunotherapy

Chairman: R. Foà

M.J. Keating

FCR

B. Eichhorst

BR

P. Hillmen

Chlorambucil plus anti-CD20 MoAb

Session III - Novel Targeted Therapies

Chairmen: P. Ghia, E. Montserrat

J.A. Burger

Ibrutinib

S.M. O'Brien

Idelalisib

P. Hillmen

Venetoclax

Tuesday, November 14, 2017

Session IV - Newer Agents

Chairmen: J.R. Brown, P.L. Zinzani

J.R. Brown

Next-generation BTK inhibitors: Acalabrutinib

C. Tam

Next-generation BTK inhibitors: BGB-3111

S.M. O'Brien

Other PI3K inhibitors: Duvelisib

S.M. O'Brien

Other PI3K inhibitors: TGR-1202

J.R. Brown

Other PI3K inhibitors: Pilaralisib

Session V - Interesting Questions

Chairmen: J.A. Burger, A. Cuneo

P. Hillmen

Is it possible to stop treatment with the new targeted therapies?

J.A. Burger

Are there advances with combinations of therapies using targeted agents?

S.M. O'Brien

Which is the best sequence of these novel agents?